Antonio Sanchez-Mulero
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer.
Journal: Journal of experimental & clinical cancer research : CR
Published: August 15, 2025
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial.
Journal: ESMO open
Published: June 16, 2025
Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy.
Journal: Cancer discovery
Published: February 21, 2023
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.
Journal: Molecular oncology
Published: September 17, 2022
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer.
Journal: Cell reports. Medicine
Published: January 24, 2022
Genetic and compound screens uncover factors modulating cancer cell response to indisulam.
Journal: Life science alliance
Published: December 22, 2021
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
Journal: Nature medicine
Published: July 04, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026